APGE
Apogee Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$135.07
−0.01%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$1.14
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$1.14
- EPS estimate
- -$1.07
- Revenue actual
- —
- Revenue estimate
- $10.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +0.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $135
- PT range
- $135 – $135
- Analysts
- 12
0 Buy12 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$1.07 | -$1.14 | Miss -6.54% | — |
| May 11, 2026 | -$1.12 | -$1.06 | Beat 5.36% | — |
| Mar 3, 2025 | -$0.94 | -$1.19 | Miss -26.60% | — |
| Mar 5, 2024 | -$0.45 | -$0.32 | Beat 28.89% | — |
| Nov 13, 2023 | -$0.38 | -$0.51 | Miss -34.21% | — |
| Jul 17, 2023 | -$1.70 | -$3.78 | Miss -122.35% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026